NeuroSearch investors thrill to trial data

Shares of NeuroSearch surged on the news that its obesity drug tesofensine produced very good data in a Phase IIb trial. The drug hit all endpoints with a high statistical significance. One analyst dubbed the data "fantastic," which did no harm to the stock value.

- see NeuroSearch's release on the results